Prescribing information and Adverse event reporting can be found at the bottom of the page
Brand Navigation Banner
Search Header
Assessing and managing women with heavy menstrual bleeding
The definition of heavy menstrual bleeding (HMB) has changed – it is no longer solely defined by millilitres of blood loss per cycle but now includes the impact on a women’s physical, social and emotional quality of life.1
>80%
of women say that HMB affects their relationship with their partner or their performance at work, and it affects attendance at school or work for 68% of sufferers.2
- HELP Group. Heavy menstrual bleeding e-learning. Return to content
- Bitzer J, et al. Open access Journal of Contraception, 2013;4:21–28. Return to content
- Hurskainen R, et al. Acta Obstetricia et Gynecologica 2007;86:749–757. Return to content
Once ‘bothersome bleeding’ has been identified, follow the HELP diagnostic pathway for HMB
*You may wish to consider other treatments after trial of pharmaceutical options as per NICE guidelines: NICE Heavy Menstrual Bleeding NG88, 2018.
The HELP protocol has been adapted in the UK to reflect the 2018 updated NICE guidelines. The HELP group is an expert panel of physicians from 12 countries with a special interest in heavy menstrual bleeding (HMB), supported and funded by Bayer.
The interactive HELP treatment algorithm, including clinical considerations for all approved treatment options
The HELP protocol has been adapted in the UK to reflect the 2018 updated NICE guidelines.
The HELP group is an expert panel of physicians from 12 countries with a special interest in heavy menstrual bleeding (HMB), supported and funded by Bayer.
These treatments are recommended for women with no identified pathology, fibroids less than 3cm in diameter, or suspected or diagnosed adenomyosis.
NICE recommends Mirena® (52mg levonorgestrel) as a first-line pharmaceutical treatment for HMB with no identified pathology.1
- Provides effective relief from idiopathic menorrhagia.2
- Achieves mean menstrual blood loss reduction of up to 96% at 12 months.3
- Reduced bleeding promotes the increase of blood haemoglobin levels in patients with menorrhagia.2
- Improves quality of life as scored by the Menorrhagia Multi-Attribute Scale (MMAS) more than usual medical treatments (tranexamic acid, mefenamic acid, combined oestrogen-progestogen, progesterone alone or medroxyprogesterone acetate).4
- Totally or occasionally absent menstruation has been associated with prolonged continuation with Mirena® (Levonorgestrel).5
- May effectively manage bleeding problems during the transition through menopause.6
- NICE clinical guidance NG88. Heavy menstrual bleeding: assessment and management, March 2018. Available at: https://www.nice.org.uk/guidance/ng88. Last accessed: May 2022. Return to content
- Bayer PLC. Mirena® Summary of Product Characteristics, 2020. Return to content
- Stewart A, et al. Br J Obs Gyn 2001;108:74–86. Return to content
- Gupta J, et al. N Engl J Med 2013;368:128–137. Return to content
- Backman T, et al. Br J Obs Gyn 2000;107:335–339. Return to content
- Depypere H and Inki P. Climacteric 2015;18:1–13. Return to content
Heavy Menstrual Bleeding (HMB): evidence-based learning for best practice.
A 30-minute, scientific e-learning course developed by the HELP expert panel of independent physicians*. Three case-based modules cover the diagnostic pathway and treatment algorithm for HMB to help you to counsel your patients effectively.
*The formation of the HELP expert panel and its ongoing work is supported by Bayer AG.
Gain real-world patient insights into heavy menstrual bleeding through this short video that can help both you and your patients relate to the condition.
Latest content
PP-PF-WHC-GB-1034 May 2022
Reporting adverse events and quality complaints
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Bayer plc.
If you want to report an adverse event or quality complaint, reports can be directed to: Tel: 01182063500 or email: pvuk@bayer.com
Further information is available on the “contact” tab at www.bayer.co.uk.
